Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research^[1][2].

Myelopeptide-2 (1 ng/mL-0.1 mg/mL; 72 h) restores phytohemagglutinin (PHA, 2.5 mg/mL)-induced proliferation of human peripheral blood T lymphocytes^[1].
Myelopeptide-2 (0.1 mg/mL and 1 mg/mL; 1-3 d) increases the level of the reduced IL-2 synthesis in human T lymphocytes damaged by HL-60 or measles virus^[1].

Myelopeptide-2 (10 μg/kg; injection; for 20-50 weeks) delays the appearance of urethane-induced tumors and decreases the number of spontaneous and urethane-induced lung tumors in mice with short-term treatment^[2].

775.93

C₄₁H₅₇N₇O₈

137833-31-9

LVVYPW

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.